Pfizer’s patents for overactive bladder drug not obvious, rules US judge

14-08-2017

Pfizer’s patents for overactive bladder drug not obvious, rules US judge

no_limit_pictures / iStockphoto.com

A US judge has ruled that five patents owned by Pfizer are not invalid as obvious, in a dispute over a generic produced by Mylan.


Pfizer, Mylan, patent, patent infringement, big pharma, ANDA, generics

LSIPR